Last reviewed · How we verify

NCT07514988

Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment

Not yet recruiting NA Last updated 7 April 2026
What this trial tests

NA trial testing Sirolimus-coated DCB in Acute Coronary Syndromes (ACS) in 60 participants. Not yet recruiting.

Timeline
1 May 2026
Primary endpoint
31 December 2027
1 July 2028

Quick facts

Lead sponsorChina National Center for Cardiovascular Diseases
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 May 2026
Primary completion31 December 2027
Estimated completion1 July 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

Adults 18 to 80, any sex, with Acute Coronary Syndromes (ACS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate and compare the local inflammatory responses and plaque healing characteristics between sirolimus-coated and paclitaxel-coated coronary drug-coated balloons in patients with acute coronary syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndromes (ACS)

Currently open trials in the same condition.

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07514988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing